GlassScriptPhysician profile
Henry A Greenblatt
NPI 1619963899
$2,705.28
in general payments reported to CMS, 2019-2025
11 companies · $457 in 2025
The $457 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $11.44 · 2021: $37.27 · 2022: $434 · 2023: $850 · 2024: $810 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,939 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,939.47 |
| Education | $177.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $500.57 | 2023-2024 | |
| Leo Pharma INC. | $454.26 | 2022-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $387.99 | 2022-2025 | Tremfya |
| Lilly USA, LLC | $331.97 | 2022-2025 | Taltz, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $294.54 | 2022-2024 | Sotyktu |
| Incyte Corporation | $256.72 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $153.40 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $150.42 | 2023-2025 | Libtayo, Dupixent |
| Abbvie INC. | $144.78 | 2019-2023 | |
| Ucb, INC. | $19.46 | 2024 | Bimzelx |
| Galderma Laboratories, L.P. | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Greenblatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.